衔接蛋白p66Shc在心肌缺血再灌注损伤中的作用研究进展  

Research progress on the role of adaptor protein p66Shc in myocardial ischemia-reperfusion injury

作　　者：王沛 剡冬冬 彭瑜[2,3] 张钲 Wang Pei;Yan Dong-Dong;Peng Yu;Zhang Zheng(The First Clinical Medical College of Lanzhou University,Lanzhou,Gansu 730000,China;Department of Cardiology,the First Hospital of Lanzhou University,Lanzhou,Gansu 730000,China;Gansu Key Laboratory of Cardiovascular Disease,Lanzhou,Gansu 730000,China)

机构地区：[1]兰州大学第一临床医学院,甘肃兰州730000 [2]兰州大学第一医院心脏中心,甘肃兰州730000 [3]甘肃省心血管病重点实验室,甘肃兰州730000

出　　处：《解放军医学杂志》2023年第4期456-460,共5页Medical Journal of Chinese People's Liberation Army

基　　金：国家自然科学基金(82060807)。

摘　　要：缺血性心脏病是全世界死亡率较高的疾病之一,长期危害着人类的健康,其首选治疗策略再灌注可导致心肌缺血恶化及加速损伤,即心肌缺血再灌注损伤(MIRI),严重影响临床疗效及患者预后。目前MIRI的预防和治疗仍是临床尚未解决的难题。大量研究表明,衔接蛋白p66Shc在包括MIRI对内的多种疾病的发生发展具有重要的调控作用。本文针对衔接蛋白p66Shc在MIRI氧化应激、炎症反应和血管内皮功能障碍中的调节作用机制,以及以p66Shc为靶点的相关治疗策略进行综述,以期为MIRI的预防和治疗提供进一步的参考。Ischemic heart disease(IHD)is one of the diseases with the highest mortality in the world,which endangers human health for a long term.Reperfusion,the preferred treatment strategy,can lead to myocardial deterioration and accelerate injury,known as myocardial ischemia-reperfusion injury(MIRI),which seriously affects the clinical efficacy and prognosis of patients.At present,the prevention and treatment of MIRI is still an unsolved clinical problem.Numerous studies have shown that adaptor protein p66Shc plays an important regulatory role in the occurrence and development of various diseases,including MIRI.The mechanism of adaptor protein p66Shc involved in oxidative stress,inflammatory response and vascular endothelial function in MIRI,and the relevant treatment strategies targeting p66Shc were reviewed in present paper in order to provide a reference for further research on prevention and treatment of MIRI.

关 键 词：缺血性心脏病 心肌缺血再灌注损伤 P66SHC 氧化应激 

分 类 号：R541[医药卫生—心血管疾病]